The European Medicines Agency accepted for review a marketing authorization application for the proposed biosimilar, FKB327, in May 2017, and the companies say that they expect to receive the EMA’s decision during the second half of 2018.
Mylan announced today that it has entered into a partnership with Fujifilm Kyowa Kirin Biologics to commercialize an adalimumab biosimilar, referencing Humira, in Europe.
The European Medicines Agency (EMA) accepted for review a marketing authorization application for the proposed biosimilar, FKB327, in May 2017, and the companies say that they expect to receive the EMA’s decision during the second half of 2018. Under the agreement, Mylan will have an exclusive license to commercialize the biosimilar in Europe and will receive an upfront fee from Fujifilm Kyowa Kirin.
In November 2017, at the American College of Rheumatology’s (ACR) 2017 Annual Meeting in San Diego, California, Fujifilm Kyowa Kirin announced results of a double-blind, phase 3 clinical trial comparing the proposed biosimilar to the reference product in 728 patients with rheumatoid arthritis (RA). The trial was followed by a randomized open-label extension study that included a switch between the 2 products.
In the double-blind study, patients with active RA that was not adequately controlled with methotrexate were randomized 1 to 1 to receive 40 mg of either FKB327 or the reference Humira every other week, with concomitant methotrexate. At week 24, 72.5% of the FKB327 group had met ACR criteria for 20% improvement (ACR20), and 74.3% of the reference group had also achieved ACR20. Disease Activity Score (measured in 28 joints with C-reactive protein) at week 24, as well as the proportions of patients who achieved ACR50 and ACR70, was also comparable. Safety profiles, mean serum trough drug concentration at a steady state, and the prevalence of anti-drug antibodies (ADA) were also comparable.
In the open-label extension, patients either continued to receive FKB327 or Humira, or switched from their first treatment to the other. ACR20 response rates were comparable after continuous and switched treatments, and no consistent differences in pharmacokinetics or ADA profiles were observed between continuous or switched treatment groups.
If approved, FKB327 will enter a European biosimilars market that is already heating up for adalimumab; Samsung Bioepis and Biogen announced last week that their approved adalimumab biosimilar, Imraldi, will launch in the European Union on October 16, 2018, the same date that Amgen plans to launch its own approved biosimilar, Amgevita.
Reference
Genovese MC, Glover J, Matsunaga N, Chisholm D, Alten R. Efficacy, safety, and immunogenicity in randomized, double-blind and open-label extension studies comparing FKB327, and adalimumab biosimilar, with the adalimumab reference product (Humira) in patients with active rheumatoid arthritis. Presented at the American College of Rheumatology 2017 meeting, November 7, 2017; San Diego, California. Abstract 2799. acrabstracts.org/abstract/efficacy-safety-and-immunogenicity-in-randomized-double-blind-db-and-open-label-extension-ole-studies-comparing-fkb327-an-adalimumab-biosimilar-with-the-adalimumab-reference-product-humira/.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.